Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder

Completed · Phase 2 · Has a placebo group

Conditions studied: PTSD

In brief

This study, conducted at the NIH and the Mount Sinai School of Medicine, will examine the effectiveness of a substance P or NK1 antagonist study drug known as GR205171 in treating the symptoms of posttraumatic stress disorder (PTSD). People between 18 and 65 years of age who have been diagnosed with PTSD may be eligible for this study. Participants undergo the following tests and procedures: Treatment: Patients are tapered off current ineffective medications over 1 to 2 weeks. All participants receive placebo (sugar pill) at the start of the study. At some point within the first 3 weeks of the study, they are then randomly assigned either to take GR205171 or to continue with placebo for the remainder of the 10-week treatment period. Clinic visits: Patients come to the clinic once a week during treatment. The following procedures are done at various visits. * Interviews, self report questionnaires and psychiatric rating scales at every visit. * Physical examination, blood and urine tests. Blood is drawn up to 10 times during the study. Follow-up visits continue for up to 3 months after the end of the study, during which patients are offered standard clinical treatment.

Key facts

Study ID

NCT00383786

Run by

Baylor College of Medicine

People needed

47

Starts

2006-09-01

Expected to finish

2009-06-01

Last updated by the study team

2019-07-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Subjects will be excluded from the study for any of the following reasons:
• Presence of psychotic features.
• Participation in a clinical trial of another investigational drug within 1 month (30 days) prior to study entry (Visit 1).
• Female subjects who are either pregnant or nursing.
• Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
• Subjects with uncorrected hypothyroidism or hyperthyroidism.
• Previous treatment with NK1 receptor antagonist.
• DSM-IV substance abuse or dependence within the past 90 days.
• Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to Visit 2.
• Treatment with a reversible MAOI, guanethidine, or guanadrel within 1 week or with fluoxetine within 6 weeks prior to Visit 2.
• Treatment with any other concomitant medication with primarily CNS activity.
• Treatment with clozapine or ECT within 12 weeks prior to Visit 2.
• Current diagnosis of schizophrenia or other psychotic disorder, bipolar disorder, other Axis I disorder (except for major depressive disorder, dysthymia and other anxiety disorders that followed exposure to the trauma) as defined in the DSM-IV.
• Patients who are currently at high risk for homicide or suicide, a score greater than 4 on item 10 of the MADRS.
• Current or planned litigation regarding the traumatic event.
• Patients will not be allowed to receive structured psychotherapy during the trial.

Where it is running

• National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
• Mt. Sinai Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.